Merck and Samsung BioLogics to further their partnership
In the growing biopharmaceutical market, manufacturers are moving toward end-to-end solutions — from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply — as they seek to cut costs while increasing quality and efficiency.
Leading science and technology company Merck has therefore signed an MoU with Samsung BioLogics to further its biopharmaceutical manufacturing and biologics process development capabilities. It acts as an extension to the MoU the companies signed back in 2014.
Samsung BioLogics is a global full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. The alliance will see the duo further grow its process development and clinical material production at small biotech start-ups focusing on novel drug development for which Samsung BioLogics acts as a contract manufacturer.
“Merck's process development expertise and Mobius, the wide single-use bioprocessing portfolio, will allow innovations to reach patients faster," commented Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Related stories
- Zebra Medical Vision aims to cater to a surging health imaging market
- Aster DM Healthcare aim to place a 10% stake on the Bombay Stock Exchange
- Mental health is having a severe impact on employment figures
The company remains a premier supplier of process development and clinical-stage manufacturing solutions, materials and services needed to produce biopharmaceutical drugs and is committed to delivering superior bioreactor technology to manufacturers worldwide.
Samsung’s one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk cGMP manufacturing of drug substance and drug product. This also includes quality assurance, quality control, regulatory compliance standards and support for its customers.
Merck has been the key solution provider for Samsung BioLogics' 30KL facility and 152KL facility in Korea, and has trained Samsung BioLogics team on building a robust biologics development process.
"This alliance will create synergy and maximize our technology potential," stated Dr. Tae-Han Kim, President and CEO of Samsung BioLogics.
